Rivaroxaban Film-Coated Tablets (20 mg),Xarelto (Rivaroxaban Film-Coated Tablets (20 mg))
Sponsors
Bio-innova and Synchron.Co.,Ltd, Bio-innova Co., Ltd.
Conditions
Healthy subjects
Bioequivalence Rivaroxaban Film-Coated Tablets (20 mg)Healthy subjects
Bioequivalence
Rivaroxaban
Phase 1
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Rivaroxaban Film-Coated Tablets (20 mg) relative to Originator Rivaroxaban Film-Coated Tablets (20 mg) in healthy Thai volunteers under fed condition
Active, not recruitingTCTR20211018006
Start: 2021-12-21Target: 30Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Rivaroxaban Film-Coated Tablets (20 mg) relative to Originator Rivaroxaban Film-Coated Tablets (20 mg) in healthy Thai volunteers under fed condition
Active, not recruitingTCTR20220629006
Start: 2023-02-07Target: 36Updated: 2026-08-03